CASTLE BIOSCIENCES INC (CSTL)
US14843C1053 - Common Stock
Taking everything into account, CSTL scores 4 out of 10 in our fundamental rating. CSTL was compared to 116 industry peers in the Health Care Providers & Services industry. While CSTL seems to be doing ok healthwise, there are quite some concerns on its profitability. CSTL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CSTL has reported negative net income.
In the past year CSTL had a positive cash flow from operations.
CSTL had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CSTL reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -6.72%, CSTL is doing worse than 61.54% of the companies in the same industry.
With a Return On Equity value of -7.65%, CSTL perfoms like the industry average, outperforming 52.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.72% | ||
| ROE | -7.65% | ||
| ROIC | N/A |
ROA(3y)-11.48%
ROA(5y)-6.86%
ROE(3y)-13.03%
ROE(5y)-7.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CSTL (80.58%) is better than 94.87% of its industry peers.
CSTL's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CSTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y0.71%
2. Health
2.1 Basic Checks
CSTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSTL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CSTL has more shares outstanding
The debt/assets ratio for CSTL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.42 indicates that CSTL is not in any danger for bankruptcy at the moment.
CSTL has a better Altman-Z score (7.42) than 94.87% of its industry peers.
CSTL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CSTL (0.02) is better than 84.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.42 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
CSTL has a Current Ratio of 9.25. This indicates that CSTL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.25, CSTL belongs to the top of the industry, outperforming 98.29% of the companies in the same industry.
A Quick Ratio of 9.02 indicates that CSTL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.02, CSTL belongs to the top of the industry, outperforming 98.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.25 | ||
| Quick Ratio | 9.02 |
3. Growth
3.1 Past
CSTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.56%, which is quite impressive.
CSTL shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.70%.
Measured over the past years, CSTL shows a very strong growth in Revenue. The Revenue has been growing by 57.33% on average per year.
EPS 1Y (TTM)57.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q91.82%
Revenue 1Y (TTM)64.7%
Revenue growth 3Y51.99%
Revenue growth 5Y57.33%
Revenue growth Q2Q73.59%
3.2 Future
CSTL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.49% yearly.
The Revenue is expected to grow by 11.14% on average over the next years. This is quite good.
EPS Next Y-1.14%
EPS Next 2Y5.13%
EPS Next 3Y18.67%
EPS Next 5Y17.49%
Revenue Next Year12.55%
Revenue Next 2Y10.49%
Revenue Next 3Y11.22%
Revenue Next 5Y11.14%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CSTL. In the last year negative earnings were reported.
Also next year CSTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CSTL's earnings are expected to grow with 18.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.13%
EPS Next 3Y18.67%
5. Dividend
5.1 Amount
CSTL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CASTLE BIOSCIENCES INC
NASDAQ:CSTL (5/17/2024, 7:00:01 PM)
After market: 24.24 0 (0%)24.24
+0.02 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap668.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.72% | ||
| ROE | -7.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.58% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.25 | ||
| Quick Ratio | 9.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)57.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)64.7%
Revenue growth 3Y51.99%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y